Genentech In Competition With Itself On Eye Drug
Article Abstract:
Avastin, a drug developed by Genentech Inc. to treat colorectal cancer, has been showing good results as an off-label treatment for macular degeneration. It is a cheaper alternative to Lucentis, which is currently being developed by Genetech, for macular degeneration.
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2005
Complications and side effects, Dosage and administration, Off-label prescribing, Off label prescribing, Avastin (Medication)
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
In Trial, Drug Aids Vision Of Elderly
Article Abstract:
Genentech reported that its experimental drug Lucentis is able to not just slow macular degeneration, but can restore vision, which is a significant improvement over other medications.
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2005
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Subjects list: United States, Product development, Drug therapy, Biological products industry, Genentech Inc., Macular degeneration, DNA, Lucentis (Medication)
Similar abstracts:
- Abstracts: Eyetech Pins Its Hopes (And Shares) On New Drug. Medical Editors Likely To Call for Registration Of Drug Tests at Outset
- Abstracts: Studies Find Biotechnology Anemia Drug Shows Promise in Treating Several Diseases. In Drug Research, Some Guinea Pigs Are Now Human
- Abstracts: NPR Conflict With Overseer Is Growing. The Net and Big Sellers Change the Diamond Business. De Beers Agrees to Guilty Plea To Re-enter the U.S. Market
- Abstracts: Safety Group Closely Echoes Rail Industry. Railroad to Pay Over Violations At Its Crossings. In Deaths at Rail Crossings, Missing Evidence and Silence
- Abstracts: Advertisers have a deep concern for the truth, especially when it comes to a rival's claims. Can't Remember the Movie? Look for an Oscar-Season Ad
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.